Stock Events

Stock Events

MetaStat 

$0
2
+$0+0% Monday 18:36

Statistics

Day High
0
Day Low
0
52W High
0
52W Low
0
Volume
16,900
Avg. Volume
70
Mkt Cap
3,526.2
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

1FebExpected
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Q4 2022
0
0.33
0.67
1
Expected EPS
0
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2016
0Revenue
-12.44MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MTST. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Guardant Health
GH
Mkt Cap11.72B
Guardant Health specializes in advanced diagnostics, including cancer profiling, directly competing with MetaStat's diagnostic technologies in cancer metastasis.
Exact Sciences
EXAS
Mkt Cap12.25B
Exact Sciences provides molecular diagnostic tests which overlap with MetaStat's focus on cancer-related diagnostics.
Fulgent Genetics
FLGT
Mkt Cap687.17M
Fulgent Genetics offers genetic testing to detect cancer, competing in the same space as MetaStat's cancer diagnostic tests.
Myriad Genetics
MYGN
Mkt Cap748.08M
Thermo Fisher Scientific
TMO
Mkt Cap214.25B
Illumina
ILMN
Mkt Cap18.99B
Illumina provides genomic sequencing solutions that are crucial for cancer research and diagnostics, competing with MetaStat's technologies.
Quest Diagnostics
DGX
Mkt Cap19.57B
Quest Diagnostics provides diagnostic testing for conditions including cancer, which competes with MetaStat's diagnostic services.

About

MetaStat, Inc., a precision medicine company, focuses on discovering and developing therapeutic and diagnostic treatment solutions for cancer patients. The company is developing novel drug candidates and companion diagnostic tests that target the MENA pathway. Its product candidates include MENA diagnostic assay, a tissue-based quantitative immunofluorescence test that measures expression of the pro-metastatic MENA protein splice-variant; companion diagnostic to predict RTK inhibitor drug responses and anti-microtubule drug responses; liquid blood-based biopsy to enhance cancer diagnosis and optimize patient care; MetaSite Breast assay, an immunohistochemistry test that measures micro-anatomical intravasat at blood vessels within the tumor microenvironment ion sites; and prognostic diagnostic to predict risk of cancer metastasis. The company's therapeutic targets a critical metastatic pathway in solid tumors responsible for driving tumor resistance and the spread of aggressive cancer. MetaStat, Inc. is based in Boston, Massachusetts.
Show more...
CEO
Mr. Frederick E. Pierce II
Employees
6
Country
US
ISIN
US59140A2033

Listings

OTC Link
US
MTST

0 Comments

Share your thoughts

FAQ

What is MetaStat stock price today?▼
The current price of MTST is $0 USD — it has increased by +0% in the past 24 hours. Watch MetaStat stock price performance more closely on the chart.
What is MetaStat stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange MetaStat stocks are traded under the ticker MTST.
What is MetaStat market cap?▼
Today MetaStat has the market capitalization of 3,526.2
What is MetaStat revenue for the last year?▼
MetaStat revenue for the last year amounts to 0 USD.
What is MetaStat net income for the last year?▼
MTST net income for the last year is -12.44M USD.
How many employees does MetaStat have?▼
As of April 01, 2026, the company has 6 employees.
In which sector is MetaStat located?▼
MetaStat operates in the Health Care sector.
When did MetaStat complete a stock split?▼
The last stock split for MetaStat was on October 08, 2015 with a ratio of 1:15.
Where is MetaStat headquartered?▼
MetaStat is headquartered in Boston, US.